Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · REGISTER · 2002-08-05 · Department of the Army, DOD · Notices

Notices. Notice

276 words·~1 min read·/register/2002/08/05/02-19714

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 3710-08-M DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning Chimeric Filovirus Glycoprotein AGENCY: Department of the Army, DOD. ACTION: Notice. SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application No. 10/066,506 entitled “Chimeric Filovirus Glycoprotein,” filed January 31, 2002. Foreign rights are also available (PCT/US02/03339).
The United States Government, as represented by the Secretary of the Army has rights in this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney,
(301)619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment,
(301)619-6664, both at telefax
(301)619-5034. SUPPLEMENTARY INFORMATION: Chimeric GP molecules were constructed which contain portions of both the EBOV and MBGV GP proteins by swapping the subunits between EBOV and MBGV. The chimeric molecules were cloned into an alphavirus replicon, which offers the advantage of high protein expression levels in mammalian cells and is a proven vaccine vector. These chimeric molecules fully protected guinea pigs from MBGV challenge, and conversely protected the animals from EBOV challenge. These results indicate that a protective epitope resides within the GP2 submit of the MBGV GP protein and at least partially within the GP2 subunit of the EBOV GP protein. Additionally these results show that a construction of a single-component bivalent vaccine protective in guinea pigs is achievable. Luz D. Ortiz, Army Federal Register Liaison Officer. [FR Doc. 02-19714 Filed 8-2-02; 8:45 am]
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Notices
Notice
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.